KR102790184B1 - 파브리병을 앓는 환자에서 심장 기능을 강화 및/또는 안정화시키는 방법 - Google Patents

파브리병을 앓는 환자에서 심장 기능을 강화 및/또는 안정화시키는 방법 Download PDF

Info

Publication number
KR102790184B1
KR102790184B1 KR1020207008736A KR20207008736A KR102790184B1 KR 102790184 B1 KR102790184 B1 KR 102790184B1 KR 1020207008736 A KR1020207008736 A KR 1020207008736A KR 20207008736 A KR20207008736 A KR 20207008736A KR 102790184 B1 KR102790184 B1 KR 102790184B1
Authority
KR
South Korea
Prior art keywords
delete delete
migalastat
patient
mwfs
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207008736A
Other languages
English (en)
Korean (ko)
Other versions
KR20200044908A (ko
Inventor
제프 카스텔리
제이 바트
니나 스쿠반
Original Assignee
아미쿠스 세라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63528948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102790184(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아미쿠스 세라퓨틱스, 인코포레이티드 filed Critical 아미쿠스 세라퓨틱스, 인코포레이티드
Priority to KR1020257010249A priority Critical patent/KR20250049561A/ko
Publication of KR20200044908A publication Critical patent/KR20200044908A/ko
Application granted granted Critical
Publication of KR102790184B1 publication Critical patent/KR102790184B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207008736A 2017-08-28 2018-08-28 파브리병을 앓는 환자에서 심장 기능을 강화 및/또는 안정화시키는 방법 Active KR102790184B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257010249A KR20250049561A (ko) 2017-08-28 2018-08-28 파브리병을 앓는 환자에서 심장 기능을 강화 및/또는 안정화시키는 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762550984P 2017-08-28 2017-08-28
US62/550,984 2017-08-28
PCT/US2018/048257 WO2019046244A1 (en) 2017-08-28 2018-08-28 METHODS FOR ENHANCING AND / OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257010249A Division KR20250049561A (ko) 2017-08-28 2018-08-28 파브리병을 앓는 환자에서 심장 기능을 강화 및/또는 안정화시키는 방법

Publications (2)

Publication Number Publication Date
KR20200044908A KR20200044908A (ko) 2020-04-29
KR102790184B1 true KR102790184B1 (ko) 2025-04-01

Family

ID=63528948

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207008736A Active KR102790184B1 (ko) 2017-08-28 2018-08-28 파브리병을 앓는 환자에서 심장 기능을 강화 및/또는 안정화시키는 방법
KR1020257010249A Pending KR20250049561A (ko) 2017-08-28 2018-08-28 파브리병을 앓는 환자에서 심장 기능을 강화 및/또는 안정화시키는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257010249A Pending KR20250049561A (ko) 2017-08-28 2018-08-28 파브리병을 앓는 환자에서 심장 기능을 강화 및/또는 안정화시키는 방법

Country Status (26)

Country Link
US (1) US20200222377A1 (https=)
EP (3) EP4588476A1 (https=)
JP (3) JP7755929B2 (https=)
KR (2) KR102790184B1 (https=)
CN (1) CN111770753A (https=)
AR (1) AR112482A1 (https=)
AU (2) AU2018326364B2 (https=)
CA (1) CA3074450C (https=)
CL (1) CL2020000491A1 (https=)
DK (2) DK3675853T3 (https=)
EA (1) EA202090564A1 (https=)
ES (2) ES2931054T3 (https=)
FI (1) FI4176877T3 (https=)
HR (2) HRP20250064T1 (https=)
HU (2) HUE060287T2 (https=)
IL (3) IL272893B2 (https=)
LT (2) LT4176877T (https=)
MX (2) MX2020002229A (https=)
PL (2) PL4176877T3 (https=)
PT (2) PT4176877T (https=)
RS (2) RS66515B1 (https=)
SG (1) SG11202001707PA (https=)
SI (1) SI4176877T1 (https=)
SM (2) SMT202200459T1 (https=)
TW (1) TWI845479B (https=)
WO (1) WO2019046244A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2573498T3 (es) 2006-05-16 2016-06-08 Amicus Therapeutics, Inc. Opciones de tratamiento para la enfermedad de Fabry
SI3470077T1 (sl) 2008-02-12 2020-12-31 Amicus Therapeutics, Inc. Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
CA3224537C (en) 2017-05-30 2025-09-09 Amicus Therapeutics, Inc. USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE
IL272893B2 (en) 2017-08-28 2024-07-01 Amicus Therapeutics Inc Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
CA3090496C (en) 2018-02-06 2024-03-26 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
EP4282472A3 (en) 2018-08-20 2024-02-21 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
EP3851105B1 (en) 2019-08-07 2026-03-04 Amicus Therapeutics, Inc. Migalastat for use in treating fabry disease in patients having a mutation in the gla gene
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
TR2024011149A1 (tr) 2024-08-23 2026-03-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Mi̇galastat i̇çeren kapsül formülasyonlari
CN119120696A (zh) * 2024-11-12 2024-12-13 北京贝瑞和康生物技术有限公司 检测法布雷病gla基因突变的引物组、试剂盒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160324839A1 (en) * 2007-04-26 2016-11-10 Amicus Therapeutics, Inc. Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU2008232614A1 (en) 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of Fabry disease using pharmacological chaperones
SI3470077T1 (sl) 2008-02-12 2020-12-31 Amicus Therapeutics, Inc. Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
IL272893B2 (en) 2017-08-28 2024-07-01 Amicus Therapeutics Inc Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
CN111344912B (zh) 2017-08-28 2021-12-28 约翰·梅扎林瓜联合股份有限公司 同轴电缆连接器的天气防护壳体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160324839A1 (en) * 2007-04-26 2016-11-10 Amicus Therapeutics, Inc. Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Lancet, 2009, 374(9706), 1986-1996*

Also Published As

Publication number Publication date
SMT202200459T1 (it) 2023-01-13
JP2025138638A (ja) 2025-09-25
MX2020002229A (es) 2020-07-20
TWI845479B (zh) 2024-06-21
RS63742B1 (sr) 2022-12-30
SG11202001707PA (en) 2020-03-30
PT3675853T (pt) 2022-11-28
HRP20250064T1 (hr) 2025-03-14
KR20250049561A (ko) 2025-04-11
IL324182A (en) 2025-12-01
EA202090564A1 (ru) 2020-06-15
EP3675853A1 (en) 2020-07-08
RS66515B1 (sr) 2025-03-31
IL272893B2 (en) 2024-07-01
IL310648A (en) 2024-04-01
SI4176877T1 (sl) 2025-03-31
AR112482A1 (es) 2019-10-30
EP3675853B1 (en) 2022-09-07
US20200222377A1 (en) 2020-07-16
AU2018326364B2 (en) 2024-08-29
IL272893A (en) 2020-04-30
CL2020000491A1 (es) 2020-09-11
IL272893B1 (en) 2024-03-01
DK4176877T3 (da) 2025-02-24
EP4176877B1 (en) 2024-12-04
MX2023005628A (es) 2023-05-24
SMT202500073T1 (it) 2025-03-12
LT3675853T (lt) 2022-12-12
EP4588476A1 (en) 2025-07-23
HUE060287T2 (hu) 2023-02-28
LT4176877T (lt) 2025-02-10
HRP20221366T1 (hr) 2023-01-06
TW201919619A (zh) 2019-06-01
ES2931054T3 (es) 2022-12-23
PL3675853T3 (pl) 2022-12-27
JP2020531550A (ja) 2020-11-05
AU2018326364A1 (en) 2020-04-09
DK3675853T3 (da) 2022-11-28
BR112020003974A2 (pt) 2020-09-01
ES3013820T3 (en) 2025-04-15
PT4176877T (pt) 2025-02-24
PL4176877T3 (pl) 2025-04-07
AU2024266945A1 (en) 2024-12-19
FI4176877T3 (fi) 2025-03-06
CN111770753A (zh) 2020-10-13
WO2019046244A1 (en) 2019-03-07
JP2023051998A (ja) 2023-04-11
CA3074450C (en) 2024-10-01
JP7755929B2 (ja) 2025-10-17
CA3074450A1 (en) 2019-03-07
KR20200044908A (ko) 2020-04-29
HUE070433T2 (hu) 2025-06-28
EP4176877A1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
KR102790184B1 (ko) 파브리병을 앓는 환자에서 심장 기능을 강화 및/또는 안정화시키는 방법
JP7784398B2 (ja) Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
KR102631805B1 (ko) 신장 손상을 갖는 파브리 환자를 치료하는 방법
AU2025217396A1 (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
JP2024122992A (ja) Ｇｌａ遺伝子にｇ９３３１ａ変異を有する患者においてファブリー病を処置する方法
JP2025131572A (ja) 腎機能障害を有する患者のファブリー病を治療する方法
AU2025200074A1 (en) Treatment of patients with classic fabry disease
JP2024161361A (ja) 妊娠患者におけるファブリー病の治療のためのミガラスタットの使用
JP2025128105A (ja) ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用
JP2026016375A (ja) Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
CN111278438A (zh) 治疗具有肾损害的法布里患者的方法
HK40085360A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40039916A (en) Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
HK40044440A (en) Treatment of patients with classic fabry disease
HK40031708A (en) Methods of treating fabry patients having renal impairment
HK40001720A (en) Methods of treating fabry disease in patients having the g9331a mutation in the gla gene

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200326

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210827

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231219

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241227

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250328

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250328

End annual number: 3

Start annual number: 1

PG1601 Publication of registration